MedPath

Clinical Assessment of Chitosan Nanoparticles on Periodontal Problems Post Steroidal Inhalation in Asthmatic Patients: Phase I Trial

Phase 1
Not yet recruiting
Conditions
Periodontal Diseases
Interventions
Registration Number
NCT06525363
Lead Sponsor
Deraya University
Brief Summary

Periodontal problems management is the most important goals of chronic asthmatic patients that adapted to use steroid inhalation for long time. Gram negative anaerobic bacteria are generally suggested as the primary cause of Periodontal problems and mechanical procedure is the treatment approach, which is performed nonsurgical or surgically. The understanding of the role of bacteria in the initiation and progression of periodontal disease has led to great interest in the use of antibiotics to suppress or eradicate pathogenic macrobiotic. Systemic antibiotics have been used in different forms of periodontal disease treatment. Systemic antibiotics can penetrate soft tissues and may target invasive organisms, can be used to treat multiple sites simultaneously, and may also affect reservoirs of bacterial reinfection such as saliva, the tonsils, and the oral mucosa. However, there may be problems associated with the use of systemic antibiotics such as the development of resistant bacteria, and potential side effects (hypersensitivity reactions, gastrointestinal discomfort, etc.). so in this study we aimed at To evaluate the effect of chitosan nanoparticle spray in management of dental problems in asthmatic patients receiving corticosteroids inhaler that support the growth of bacteria in periodontal area.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Age from 18-50 years old
  • Both sex male and female
  • Patients diagnosed as Asthmatic
  • Patients treated with corticosteroids inhaler or ( beta2-adrenergic agonist inhaler or nebulizer for their symptoms)
Exclusion Criteria
  • Patients treated with other medication
  • Patients not diagnosed as asthmatic
  • Comorbidity

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
treatment groupChitosanchitosan nanoparticles spray 1% w/w twice daily
Primary Outcome Measures
NameTimeMethod
Levels of oral Streptococcus mutanseach 3 weeks for 12 weeks

counting number of of S. mutans will be obtained by culture and be expressed in colony forming units (CFUs)

Plaque Examinationeach 3 weeks for 12 weeks

Plaque is recorded using the plaque index (PI)

The inflammatory status of the gingivaeach 3 weeks for 12 weeks

recorded using the gingival index (GI)

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath